Brief: CorMedix To Acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence In Acute Care Settings

CorMedix

07/08/2025 13:33

Aug 7 (Reuters) - CorMedix Inc CRMD.O:

CORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS

CORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS

CORMEDIX INC - SELLING SHAREHOLDERS TO RECEIVE $300 MILLION INCLUDING $40 MILLION EQUITY

CORMEDIX INC - DEAL EXPECTED TO BE NEAR-TERM ACCRETIVE TO EPS WITH DOUBLE-DIGIT ACCRETION EXPECTED IN 2026

CORMEDIX INC: ANNUAL RUN-RATE SYNERGIES EXPECTED TO BE ABOUT $35 TO $45 MILLION

CORMEDIX INC - PRO FORMA 2025 COMBINED REVENUES ESTIMATED AT $305-$335 MILLION

CORMEDIX INC - TO PAY $300 MILLION UPFRONT

Source text: ID:nGNX4GyzDw

Further company coverage: CRMD.O

 ((Reuters.Briefs@thomsonreuters.com;))